Collegium Pharmaceutical, Inc. Q2 2026 Earnings Recap

Collegium Pharmaceutical's shares dropped 17.5% following the earnings release, driven primarily by weakness in the NUCYNTA pain franchise due to pricing pressure from authorized generics and cautious outlook on sustaining pain portfolio revenue. Despite growth in the ADHD franchise, overall expectations for pain segment durability appear to have weighed heavily on investor sentiment.

Key Takeaways

• Jornay PM prescriptions grew 13.1% year-over-year, generating $46.1 million in net revenue, up 41% year-over-year, with prescribers reaching a record 30,000, up 17.6%.
• The acquisition of Azstarys in May has expanded the ADHD portfolio, with revenue expectations raised to $65-$75 million for the partial year.
• Pain portfolio revenue totaled $140.9 million, with Belbuca up 10% year-over-year but offset by NUCYNTA revenue declines due to authorized generic pricing impacts.
• Formulary access was expanded by 9 million lives for Belbuca, effective in Q4, but concerns remain about the pain franchise's sustainability.
• Company reiterated confidence in full-year ADHD revenue targets but signaled ongoing challenges in maximizing and maintaining pain portfolio returns amid pricing pressures.